AMEX · Biotechnology

Actinium Pharmaceuticals, Inc. (ATNM) Stock

$1.05 +5.00% AMEX: ATNM Healthcare

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies.

Valuation

MetricValue
Price$1.05
Market Cap$32.94M
P/E Ratio-1.07
P/B Ratio4.59
P/S Ratio411.36
EPS (TTM)$0.00
52-Week High$1.74
52-Week Low$0.73
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-425.00%
ROA-65.38%
ROCE-450.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin-260.79%
Debt/Equity0.66
Current Ratio6.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$1.0M$0$0$0
Operating Profit$-25.0M$-34.0M$-52.0M$-42.0M$-36.0M
Net Profit$-25.0M$-33.0M$-49.0M$-38.0M$-34.0M
EPS$-1.20$-1.37$-1.83$-1.27$-1.09
Op Margin-2182.2%-3311.1%-64098.8%—-40274.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$80.0M$114.0M$81.0M$77.0M$52.0M
Total Liabilities$7.0M$48.0M$45.0M$44.0M$44.0M
Cash$78.0M$109.0M$77.0M$73.0M$48.0M
Borrowings$0$3.0M$2.0M$2.0M$2.0M

Latest News

US to Impose 25% Section 301 Tariff on Certain Brazilian Imports MT Newswires · Jul 17, 2026 Fed's Jefferson Open to Rate Hike If Inflation Persists MT Newswires · Jul 17, 2026 Benchmark (BHE): Buy, Sell, or Hold Post Q1 Earnings? StockStory · Jul 17, 2026 Rapidus and Cadence Partner on Agentic AI for Advanced SoC Design Business Wire · Jul 17, 2026 Hazardous Canadian wildfire smoke choking millions in US AFP · Jul 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-21.0M$9.0M$-47.0M$-33.0M$-25.0M
Investing Cash Flow$0$-1.0M$0$0$0
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$14.0M$31.0M$-33.0M$-4.0M$-25.0M
Free Cash Flow$-21.0M$8.0M$-47.0M$-33.0M$-25.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-0.19
FCF Yield-70.90%
Quick Ratio4.08
Interest Coverage0.00
Return 1Y-38.58%
Return 3Y-86.91%
Return 5Y-87.25%

Ownership

Insiders Held2.35%
Institutions Held20.61%
Institutions Float Held21.10%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC1,255,5162026-03-31
Acadian Asset Management. LLC600,8192026-03-31
Millennium Management Llc564,6002026-03-31
Renaissance Technologies, LLC471,6002026-03-31
Blackrock Inc.371,2102026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ANVS $1.38 -18.82% -1.54 $58.71M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
KZR $7.29 +0.00% -0.96 $53.86M 0.00%
LVTXLAVA Therapeutics N.V. $1.74 -3.87% -2.42 $45.77M 0.00%
OKUR $3.56 +0.56% -1.01 $144.17M 0.00%

About Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing and commercializing treatments, primarily focusing on those for bone marrow transplant (BMT) or other cellular and adoptive cell therapies. Its leading drug candidate, I-131 apamistamab (known as Iomab-B), is currently in a crucial Phase III clinical trial for its role in conditioning elderly patients with relapsed or refractory acute myeloid leukemia prior to BMT. Additionally, Iomab-B is being evaluated in a Phase I study for its use with CD19-targeted CAR T-cell therapy, a partnership with Memorial Sloan Kettering Cancer Center. The company's pipeline also includes several clinical and preclinical development programs that harness various isotopes such as Actinium-225, Iodine-131, and Lutetium-177. These programs are designed to target a range of validated cancer markers, including CD45, CD33, CD38, CD47, HER2, and HER3. Their applications span targeted conditioning regimens for cell and gene therapies, such as bone marrow transplantation, and as standalone or combination cancer therapeutics. Actinium has established strategic alliances, including a collaboration with Astellas Pharma, Inc. to create theranostics for solid tumor indications. Another partnership is with EpicentRx, Inc., concentrating on an innovative CD47 immunotherapy delivered via targeted radiotherapy. Furthermore, the company is working with AVEO Oncology on developing a HER3-targeting Antibody-Radio Conjugate (ARC) for solid tumors. Incorporated in 2000, Actinium Pharmaceuticals, Inc. is headquartered in New York, New York.

Actinium Pharmaceuticals, Inc. is led by CEO Sandesh C. Seth, employs 31 people, headquartered in US, publicly traded since 2012.

Actinium Pharmaceuticals, Inc. (ATNM) stock trades at $1.05 with a market capitalization of $32.94M. The stock is valued at a price-to-earnings (P/E) ratio of -1.07, price-to-book of 4.59, price-to-sales of 411.36. Over the past 52 weeks the stock has ranged between $0.73 and $1.74, and currently trades 39.7% below its 52-week high.

On profitability, Actinium Pharmaceuticals, Inc. generates a return on equity (ROE) of -425.00%, return on capital employed of -450.00%, an operating margin of 0.00%, a net profit margin of -260.79%.

Official website: www.actiniumpharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1149.22 -0.89% JNJ Drug Manufacturers - General $276.92 -0.54% ABBV Drug Manufacturers - General $258.59 -0.62% MRK Drug Manufacturers - General $151.41 -0.61% UNH Medical - Healthcare Plans $400.78 -0.04% NVS Drug Manufacturers - General $160.60 -1.53% AZN Drug Manufacturers - General $163.51 -0.76% AMGN Drug Manufacturers - General $440.55 -0.80% TMO Medical - Diagnostics & Research $611.83 -1.07% NVO Biotechnology $47.51 +1.58% ABT Medical - Devices $108.70 -0.08% GILD Drug Manufacturers - General $150.89 -0.22%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides